
The liver is the body’s control tower for metabolism, powering vital functions like converting nutrients to glucose, storing fat and breaking down toxins. Over a third of the world, however, is thought to be affected by conditions including metabolic dysfunction-associated steatotic liver disease (MASLD), which jeopardize key liver functions as the condition progresses. Hepatocyte organoids—the miniature, 3D models of the organ—hold immense promise for accelerating drug development and advancing regenerative therapies.
In a study published in Nature, Keio University researchers unveiled a method to proliferate these hard-to-grow organoids by a million-fold in just 3–4 weeks while maintaining key liver functions. “These organoids are potentially the closest laboratory representations of the liver and its multifunctionality,” says senior author Professor Toshiro Sato of the Keio University School of Medicine.
While organoids aim to mimic human organs, the liver’s repertoire of complex functions—and thus the energy it needs to operate—have made it challenging for researchers to grow organoids that proliferate and fully function, says Sato. When prioritizing growth and survival in laboratory settings, hepatocytes, the liver’s main cells, eventually transform into cells resembling cholangiocytes, which line the bile duct. Hepatocyte functions only last 1–2 weeks at most.